Last reviewed · How we verify
2-year treatment with icotinib — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
2-year treatment with icotinib (2-year treatment with icotinib) — Betta Pharmaceuticals Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 2-year treatment with icotinib TARGET | 2-year treatment with icotinib | Betta Pharmaceuticals Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 2-year treatment with icotinib CI watch — RSS
- 2-year treatment with icotinib CI watch — Atom
- 2-year treatment with icotinib CI watch — JSON
- 2-year treatment with icotinib alone — RSS
Cite this brief
Drug Landscape (2026). 2-year treatment with icotinib — Competitive Intelligence Brief. https://druglandscape.com/ci/2-year-treatment-with-icotinib. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab